INDEX 471 Fluorescence-activated cell sorting, 7 FMRFamide-related peptides (FaRPs), 360, 378–84 alternative splicing, 382 cestodes/trematodes, 391–2 nematodes: genes, 383 muscle cell actions, 382 nomenclature, 380 receptor diversity, 383–4 sodium-channel gating, 383 structure, 381–2 Folate metabolism, 192, 193, 408 antagonists, 407 resistance, 407–10 Fructokinase, 128 Fructose-1,6-bisphosphate aldolase, 128 Furazolidine, 425, 453, 454–5 G-protein-coupled receptors, 257 GABA, 359, 360, 372 Ascaris muscle response, 372 cestode/trematode neuro<strong>trans</strong>mission, 389 single-channel current activation, 372, 373 GABA receptors, 372 -cystathionase, 186 -glutamyl-cysteine synthase, 192, 415 Gastrodermis (gastrovascular cavity), 302–3, 309–11 GEET genes, 83 <strong>trans</strong>cription regulation, 73 Gene conversion, variant surface glycoprotein (VSG) switching, 99, 101 Gene expression regulation, 67, 68 Genetic maps, 6 physical, 7–8 Genome, 20 organization, 18 size, 4, 5, 18 Genome sequencing, 4, 8–14 data analysis, 16 expressed sequence tags (EST), 8–10 genome survey sequences (GSS), 10, 11 map-based, 10–11 reference strains, 13–14 shotgun sequencing, 11 error rate, 13 preliminary data releases, 13 whole chromosomes/whole genomes, 11–13 Genome survey sequences (GSS), 10, 11 Genomics, 3–27 dataset bioinformatics, 14–17 parasitic groups, 4–6, 18–26 information sources, 18, 19–20 research aims, 3–4 study methods, 6–14 whole genome assays, 17–18 Giardia, 125 calcium-binding proteins, 251, 252 mitogen-activated protein (MAP) kinases, 268, 270 Giardia duodenalis, see Giardia intestinalis Giardia intestinalis, 125, 397, 436, 437 amino acid metabolism, 183, 185, 187, 188 glutamate dehydrogenases, 182 amitochondriate state, 282, 283 chemotherapy, 425, 453–4 drug resistance, 135, 425 class II <strong>trans</strong>cription of protein coding genes, 56–7 cysteine uptake, 173 energy metabolism, 130, 133, 134, 135, 136 subcellular organization, 127 genome, 22 proteolytic enzymes, 176, 181 purine metabolism, 198, 208, 216–17 pyrimidine metabolism, 198, 206, 222 20S proteasome, 177 Giardia lamblia, see Giardia intestinalis Girardia tigrina, 392 glc-1, 374, 376 glc-2, 375 glc-3, 374 Globodera pallida,25 Glossina,90 glr-1, 373 Glucokinase, 128, 136 Gluconeogenesis, 340 Glucose phosphate isomerase, 158 Glucose <strong>trans</strong>porter 1 (GLUT1), 157, 307 Glucose <strong>trans</strong>porter 5 (GLUT5), 158 Glucose <strong>trans</strong>porters: Plasmodium falciparum, 156, 157–8 Schistosoma, 307 trypanosomes, 144 Glucose uptake: cestodes, 300 nematodes, 318, 330 Plasmodium falciparum, 155, 156, 157–8 trematodes, 306–7 Glucose-6-phosphatase, 341
472 INDEX Glucose-6-phosphate dehydrogenase, 150, 151 Glucose-6-phosphate dehydrogenase deficiency, 445, 446, 454 Glucose-6-phosphate dehydrogenase- 6-phosphogluconolactonase, 160 Glucosephosphate isomerase, 128, 145 Glutamate, 360, 373–8 cestode/trematode neuro<strong>trans</strong>mission, 389 electrophysiology, 375 excitatory effects, 373 structure, 361 Glutamate dehydrogenase, 171, 182–3 Glutamate receptors, 373 Glutamate-gated chloride channel subunits, 373–5 cloning, 375–6 Glutamine: catabolism, 185 uptake, 173 Glutathione peroxidase, 327 Glutathione synthesis, 192–3 Glutathione synthetase, 192 Glyceraldehyde-3-phosphate dehydrogenase, 130, 136, 143, 146, 159 inhibitors, 146–7 Glycerol carriers, 144, 300 Glycerol kinase, 147 Glycerol-3-phosphate dehydrogenase, 130, 141, 143, 147, 162, 449 inhibitors, 147 Glycerol-3-phosphate oxidase, 449 Glycerolphosphate phosphatase, 130 Glycocalyx: cestode tegument, 298, 299 immune evasion, 302 trematodes, 304–5 Glycogen metabolism, 340–1 Glycogen phosphorylase, 128, 340 Glycogen synthase, 340 GSII, 340 Glycolipids, nematode immune evasion, 327 Glycolysis: amitochondriate organisms, 126, 127 helminths, 341–4 drug targets, 343 Plasmodium falciparum, 155, 156, 158–60 Trypanosomatidae, 140–9 Glycoproteins, nematode immune evasion, 327, 328 Glycosome, 74, 75, 140, 141, 151–2 energy metabolism, 141, 142 enzymes, 145, 146, 147, 148 evolutionary aspects, 152 hexose-monophosphate pathway, 150 metabolite <strong>trans</strong>porters, 144 Glycosylation, 73 Glycosylinositolphospholipids, 235–6 structure, 232, 235 type I/type II, 235 Glycosylphosphatidylinositol (GPI) anchors, 225 GP63, 236 Leishmania lipophosphoglycan (LPG), 115 lipopeptidophosphoglycan, 230–1 procyclins (PARP proteins), 93, 227, 228 trematode glycocalyx, 305 Trypanosoma cruzi surface mucins, 230 variant surface glycoproteins (VSGs), 92–3, 96, 226 GMP reductase, 208, 215 GMP synthetase, 208 GP63, 177, 236 glycosylphosphatidylinositol (GPI) anchor, 236 structure, 232, 236 GPEET, <strong>trans</strong>cription regulation, 78, 79 GPEET protein, 78 GPEET-2, 228 GPEET-procyclins, 227, 228 Granins, 255 GRESAG4, 260 Guanine deaminase (GD), 208, 211, 214 Guanine phosphoribosyl<strong>trans</strong>ferase (GPRT), 208, 216 Guanylyl cyclases, 257, 258, 259 Plasmodium, 262–4 Guide RNA (gRNA)-directed editing, 39, 41–2 Gyrocotyle fimbriata, 389 H excretion, nematodes, 324–5 Haemonchus contortus: alimentary tract, 329, 335 digestive processes, 329 excretion, 333 cuticle, 315 drug absorption, 326, 327 drug resistance, 428 energy metabolism, 339, 347, 353 GABA receptors, 372 glutamate-gated chloride channel (GluCl) subunits, 375, 376 nutrient absorption, 318 P-glycoproteins (pgps), 334 proteolytic enzymes, 178 tubular system, 337
- Page 2 and 3:
Molecular Medical Parasitology
- Page 4 and 5:
Molecular Medical Parasitology Edit
- Page 6 and 7:
Contents List of contributors Prefa
- Page 8 and 9:
List of contributors Mark Blaxter,
- Page 10 and 11:
LIST OF CONTRIBUTORS ix Richard. J.
- Page 12 and 13:
Preface Parasitology was born as th
- Page 14 and 15:
S E C T I O N I MOLECULAR BIOLOGY
- Page 16 and 17:
C H A P T E R 1 Parasite genomics M
- Page 18 and 19:
TABLE 1.1 Parasite genomes: genome
- Page 20 and 21:
GENERATING GENOMICS DATA 7 differen
- Page 22 and 23:
GENERATING GENOMICS DATA 9 TABLE 1.
- Page 24 and 25:
GENERATING GENOMICS DATA 11 called
- Page 26 and 27:
GENERATING GENOMICS DATA 13 200 000
- Page 28 and 29:
BIOINFORMATICS AND THE ANALYSIS OF
- Page 30 and 31:
THE POST-GENOMICS ERA, AND THE OTHE
- Page 32 and 33:
THE PARASITES AND THEIR GENOMES 19
- Page 34 and 35:
THE PARASITES AND THEIR GENOMES 21
- Page 36 and 37:
THE PARASITES AND THEIR GENOMES 23
- Page 38 and 39:
THE PARASITES AND THEIR GENOMES 25
- Page 40 and 41:
FURTHER READING 27 treated with a d
- Page 42 and 43:
C H A P T E R 2 RNA processing in p
- Page 44 and 45:
TRANS-SPLICING 31 cis trans Exon 1
- Page 46 and 47:
TRANS-SPLICING 33 snRNPs (small nuc
- Page 48 and 49:
TRANS-SPLICING 35 trans cis U2AF35
- Page 50 and 51:
RNA EDITING 37 P AAAA... AAAA... AA
- Page 52 and 53:
RNA EDITING 39 entire transcript re
- Page 54 and 55:
RNA EDITING 41 5 Editing block C Ed
- Page 56 and 57:
RNA EDITING 43 microscopy) approach
- Page 58 and 59:
FURTHER READING 45 Nilsen, T.W. (19
- Page 60 and 61:
C H A P T E R 3 Transcription Arthu
- Page 62 and 63:
UNUSUAL MODES OF TRANSCRIPTION IN T
- Page 64 and 65:
CLASS I TRANSCRIPTION IN TRYPANOSOM
- Page 66 and 67:
CLASS I TRANSCRIPTION IN TRYPANOSOM
- Page 68 and 69:
CLASS I TRANSCRIPTION IN TRYPANOSOM
- Page 70 and 71:
CLASS II TRANSCRIPTION OF PROTEIN C
- Page 72 and 73:
SL RNA AND U snRNA GENE TRANSCRIPTI
- Page 74 and 75:
SL RNA AND U snRNA GENE TRANSCRIPTI
- Page 76 and 77:
SL RNA AND U snRNA GENE TRANSCRIPTI
- Page 78 and 79:
FURTHER READING 65 and switching in
- Page 80 and 81:
C H A P T E R 4 Post-transcriptiona
- Page 82 and 83:
POST-TRANSCRIPTIONAL REGULATION IN
- Page 84 and 85:
POST-TRANSCRIPTIONAL REGULATION IN
- Page 86 and 87:
POST-TRANSCRIPTIONAL REGULATION IN
- Page 88 and 89:
POST-TRANSCRIPTIONAL REGULATION IN
- Page 90 and 91:
POST-TRANSCRIPTIONAL REGULATION IN
- Page 92 and 93:
POST-TRANSCRIPTIONAL REGULATION IN
- Page 94 and 95:
POST-TRANSCRIPTIONAL REGULATION IN
- Page 96 and 97:
POST-TRANSCRIPTIONAL REGULATION IN
- Page 98 and 99:
POST-TRANSCRIPTIONAL REGULATION IN
- Page 100 and 101:
FURTHER READING 87 inhibition, it m
- Page 102 and 103:
C H A P T E R 5 Antigenic variation
- Page 104 and 105:
ANTIGENIC VARIATION AT THE STRUCTUR
- Page 106 and 107:
ANTIGENIC VARIATION AT THE STRUCTUR
- Page 108 and 109:
VSG Signal sequence Amino-terminal
- Page 110 and 111:
GENETICS OF ANTIGENIC VARIATION 97
- Page 112 and 113:
GENETICS OF ANTIGENIC VARIATION 99
- Page 114 and 115:
GENETICS OF ANTIGENIC VARIATION 101
- Page 116 and 117:
IMMUNE RESPONSES TO TRYPANOSOME INF
- Page 118 and 119:
INNATE RESISTANCE, HUMAN SUSCEPTIBI
- Page 120 and 121:
ANTIGENIC VARIATION IN MALARIA 107
- Page 122 and 123:
FURTHER READING 109 ACKNOWLEDGEMENT
- Page 124 and 125:
C H A P T E R 6 Genetic and genomic
- Page 126 and 127:
‘FORWARD’ VS. ‘REVERSE’ GEN
- Page 128 and 129:
EXAMPLES OF ‘FORWARD’ GENETIC A
- Page 130 and 131:
EXAMPLES OF ‘FORWARD’ GENETIC A
- Page 132 and 133:
REVERSE GENETICS AND LEISHMANIA VIR
- Page 134 and 135:
VALIDATION OF CANDIDATE VIRULENCE G
- Page 136 and 137:
S E C T I O N II BIOCHEMISTRY AND C
- Page 138 and 139:
C H A P T E R 7 Energy metabolism P
- Page 140 and 141:
SUBCELLULAR ORGANIZATION OF AMITOCH
- Page 142 and 143:
CELL MEMBRANE Fructose [b] Glucose
- Page 144 and 145:
STEPS OF AMITOCHONDRIATE CORE METAB
- Page 146 and 147:
ENZYMATIC DIFFERENCES BETWEEN AMITO
- Page 148 and 149:
ACTION OF NITROIMIDAZOLE DRUGS 135
- Page 150 and 151:
ENVOI 137 unambiguously reflect the
- Page 152 and 153:
FURTHER READING 139 Saavedra-Lira,
- Page 154 and 155:
THE EMBDEN-MEYERHOF-PARNAS (EMP) PA
- Page 156 and 157:
THE EMBDEN-MEYERHOF-PARNAS (EMP) PA
- Page 158 and 159:
THE EMBDEN-MEYERHOF-PARNAS (EMP) PA
- Page 160 and 161:
THE EMBDEN-MEYERHOF-PARNAS (EMP) PA
- Page 162 and 163:
THE EMBDEN-MEYERHOF-PARNAS (EMP) PA
- Page 164 and 165:
WHY DO TRYPANOSOMATIDAE HAVE GLYCOS
- Page 166 and 167:
FURTHER READING 153 for use in agri
- Page 168:
CARBOHYDRATE METABOLISM 155 as a hu
- Page 171 and 172:
158 ENERGY METABOLISM - APICOMPLEXA
- Page 173 and 174:
160 ENERGY METABOLISM - APICOMPLEXA
- Page 175 and 176:
162 ENERGY METABOLISM - APICOMPLEXA
- Page 177 and 178:
164 ENERGY METABOLISM - APICOMPLEXA
- Page 179 and 180:
166 ENERGY METABOLISM - APICOMPLEXA
- Page 181 and 182:
168 ENERGY METABOLISM - APICOMPLEXA
- Page 183 and 184:
This Page Intentionally Left Blank
- Page 185 and 186:
172 PROTEIN METABOLISM PROTEINS (1)
- Page 187 and 188:
174 PROTEIN METABOLISM the C-termin
- Page 189 and 190:
176 PROTEIN METABOLISM and also, to
- Page 191 and 192:
178 PROTEIN METABOLISM values rangi
- Page 193 and 194:
180 PROTEIN METABOLISM of the plasm
- Page 195 and 196:
182 PROTEIN METABOLISM in vivo, in
- Page 197 and 198:
184 PROTEIN METABOLISM PROLINE Poly
- Page 199 and 200:
186 PROTEIN METABOLISM CO 2 Dec-SAM
- Page 201 and 202:
188 PROTEIN METABOLISM a cMDH has b
- Page 203 and 204:
190 PROTEIN METABOLISM Urea ARGININ
- Page 205 and 206:
192 PROTEIN METABOLISM been describ
- Page 207 and 208:
194 PROTEIN METABOLISM absence of g
- Page 209 and 210:
This Page Intentionally Left Blank
- Page 211 and 212:
198 PURINES AND PYRIMIDINES enable
- Page 213 and 214:
200 PURINES AND PYRIMIDINES provide
- Page 215 and 216:
202 PURINES AND PYRIMIDINES activit
- Page 217 and 218:
204 PURINES AND PYRIMIDINES physiol
- Page 219 and 220:
206 PURINES AND PYRIMIDINES Amitoch
- Page 221 and 222:
208 PURINES AND PYRIMIDINES their a
- Page 223 and 224:
210 PURINES AND PYRIMIDINES FIGURE
- Page 225 and 226:
212 PURINES AND PYRIMIDINES FIGURE
- Page 227 and 228:
214 PURINES AND PYRIMIDINES protein
- Page 229 and 230:
216 PURINES AND PYRIMIDINES FIGURE
- Page 231 and 232:
218 PURINES AND PYRIMIDINES FIGURE
- Page 233 and 234:
220 PURINES AND PYRIMIDINES in Plas
- Page 235 and 236:
222 PURINES AND PYRIMIDINES whereas
- Page 237 and 238:
This Page Intentionally Left Blank
- Page 239 and 240:
226 TRYPANOSOMATID CARBOHYDRATES AF
- Page 241 and 242:
228 TRYPANOSOMATID CARBOHYDRATES In
- Page 243 and 244:
230 TRYPANOSOMATID CARBOHYDRATES po
- Page 245 and 246:
232 TRYPANOSOMATID CARBOHYDRATES LP
- Page 247 and 248:
234 TRYPANOSOMATID CARBOHYDRATES re
- Page 249 and 250:
236 TRYPANOSOMATID CARBOHYDRATES sc
- Page 251 and 252:
A. sAP COOH [T][T](S/T)(S/T)(S/T)SS
- Page 253 and 254:
240 TRYPANOSOMATID CARBOHYDRATES Cr
- Page 255 and 256:
242 INTRACELLULAR SIGNALING protein
- Page 257 and 258:
244 INTRACELLULAR SIGNALING FIGURE
- Page 259 and 260:
246 INTRACELLULAR SIGNALING 212.5 2
- Page 261 and 262:
248 INTRACELLULAR SIGNALING cycle.
- Page 263 and 264:
250 INTRACELLULAR SIGNALING V-H -A
- Page 265 and 266:
252 INTRACELLULAR SIGNALING domain)
- Page 267 and 268:
254 INTRACELLULAR SIGNALING the kno
- Page 269 and 270:
256 INTRACELLULAR SIGNALING from in
- Page 271 and 272:
258 INTRACELLULAR SIGNALING FIGURE
- Page 273 and 274:
260 INTRACELLULAR SIGNALING ESAG4 (
- Page 275 and 276:
262 INTRACELLULAR SIGNALING and ind
- Page 277 and 278:
264 INTRACELLULAR SIGNALING ATPase
- Page 279 and 280:
266 INTRACELLULAR SIGNALING G11XG
- Page 281 and 282:
268 INTRACELLULAR SIGNALING a diffe
- Page 283 and 284:
270 INTRACELLULAR SIGNALING rapid l
- Page 285 and 286:
272 INTRACELLULAR SIGNALING cells w
- Page 287 and 288:
274 INTRACELLULAR SIGNALING PfPPJ i
- Page 289 and 290:
276 INTRACELLULAR SIGNALING is cont
- Page 291 and 292:
278 PLASTIDS, MITOCHONDRIA, AND HYD
- Page 293 and 294:
280 PLASTIDS, MITOCHONDRIA, AND HYD
- Page 295 and 296:
282 PLASTIDS, MITOCHONDRIA, AND HYD
- Page 297 and 298:
284 PLASTIDS, MITOCHONDRIA, AND HYD
- Page 299 and 300:
286 PLASTIDS, MITOCHONDRIA, AND HYD
- Page 301 and 302:
288 PLASTIDS, MITOCHONDRIA, AND HYD
- Page 303 and 304:
290 PLASTIDS, MITOCHONDRIA, AND HYD
- Page 305 and 306:
292 PLASTIDS, MITOCHONDRIA, AND HYD
- Page 307 and 308:
294 PLASTIDS, MITOCHONDRIA, AND HYD
- Page 309 and 310:
This Page Intentionally Left Blank
- Page 311 and 312:
298 HELMINTH SURFACES Important exc
- Page 313 and 314:
300 HELMINTH SURFACES protease inhi
- Page 315 and 316:
302 HELMINTH SURFACES volume, there
- Page 317 and 318:
304 HELMINTH SURFACES projecting si
- Page 319 and 320:
306 HELMINTH SURFACES schistosome t
- Page 321 and 322:
308 HELMINTH SURFACES re-establish
- Page 323 and 324:
310 HELMINTH SURFACES hepatic cells
- Page 325 and 326:
312 HELMINTH SURFACES lungs. Larvae
- Page 327 and 328:
314 HELMINTH SURFACES cuticle, whic
- Page 329 and 330:
316 HELMINTH SURFACES cuticle in th
- Page 331 and 332:
318 HELMINTH SURFACES mec-8 or sym-
- Page 333 and 334:
320 HELMINTH SURFACES current, when
- Page 335 and 336:
322 HELMINTH SURFACES The cuticle-h
- Page 337 and 338:
324 HELMINTH SURFACES are typically
- Page 339 and 340:
326 HELMINTH SURFACES or carrier pr
- Page 341 and 342:
328 HELMINTH SURFACES of tyrosine-b
- Page 343 and 344:
330 HELMINTH SURFACES blood. The ge
- Page 345 and 346:
332 HELMINTH SURFACES Mutations in
- Page 347 and 348:
334 HELMINTH SURFACES in the hypode
- Page 349 and 350:
336 HELMINTH SURFACES (including H-
- Page 351 and 352:
338 HELMINTH SURFACES Blaxter, M.L.
- Page 353 and 354:
340 ENERGY METABOLISM IN HELMINTHS
- Page 355 and 356:
342 ENERGY METABOLISM IN HELMINTHS
- Page 357 and 358:
344 ENERGY METABOLISM IN HELMINTHS
- Page 359 and 360:
346 ENERGY METABOLISM IN HELMINTHS
- Page 361 and 362:
348 ENERGY METABOLISM IN HELMINTHS
- Page 363 and 364:
350 ENERGY METABOLISM IN HELMINTHS
- Page 365 and 366:
352 ENERGY METABOLISM IN HELMINTHS
- Page 367 and 368:
354 ENERGY METABOLISM IN HELMINTHS
- Page 369 and 370:
356 ENERGY METABOLISM IN HELMINTHS
- Page 371 and 372:
358 ENERGY METABOLISM IN HELMINTHS
- Page 373 and 374:
360 NEUROTRANSMITTERS CO 2 H NH 2 G
- Page 375 and 376:
362 NEUROTRANSMITTERS TABLE 15.1 An
- Page 377 and 378:
364 NEUROTRANSMITTERS more arms tha
- Page 379 and 380:
366 NEUROTRANSMITTERS the surroundi
- Page 381 and 382:
368 NEUROTRANSMITTERS proteins requ
- Page 383 and 384:
370 NEUROTRANSMITTERS FIGURE 15.11
- Page 385 and 386:
372 NEUROTRANSMITTERS FIGURE 15.13
- Page 387 and 388:
374 NEUROTRANSMITTERS sensitivity t
- Page 389 and 390:
376 NEUROTRANSMITTERS TABLE 15.3 Cl
- Page 391 and 392:
378 NEUROTRANSMITTERS crossed the c
- Page 393 and 394:
380 NEUROTRANSMITTERS have been tes
- Page 395 and 396:
382 NEUROTRANSMITTERS C-terminals a
- Page 397 and 398:
384 NEUROTRANSMITTERS Davis and Str
- Page 399 and 400:
386 NEUROTRANSMITTERS Cephalic gang
- Page 401 and 402:
388 NEUROTRANSMITTERS myoexcitation
- Page 403 and 404:
390 NEUROTRANSMITTERS is phosphoryl
- Page 405 and 406:
392 NEUROTRANSMITTERS many other an
- Page 407 and 408:
This Page Intentionally Left Blank
- Page 409 and 410:
This Page Intentionally Left Blank
- Page 411 and 412:
398 DRUG RESISTANCE of some of the
- Page 413 and 414:
400 DRUG RESISTANCE It is now estim
- Page 415 and 416:
402 DRUG RESISTANCE is again assume
- Page 417 and 418:
404 DRUG RESISTANCE An alternative
- Page 419 and 420:
406 DRUG RESISTANCE clinical eviden
- Page 421 and 422:
408 DRUG RESISTANCE FIGURE 16.4 Fol
- Page 423 and 424:
410 DRUG RESISTANCE Using similar s
- Page 425 and 426:
412 DRUG RESISTANCE whether these r
- Page 427 and 428:
414 DRUG RESISTANCE FIGURE 16.5 Str
- Page 429 and 430:
416 DRUG RESISTANCE FIGURE 16.6 Try
- Page 431 and 432:
418 DRUG RESISTANCE has permitted e
- Page 433 and 434: 420 DRUG RESISTANCE FIGURE 16.7 Dru
- Page 435 and 436: 422 DRUG RESISTANCE near future. Th
- Page 437 and 438: 424 DRUG RESISTANCE million new inf
- Page 439 and 440: 426 DRUG RESISTANCE some 50 million
- Page 441 and 442: 428 DRUG RESISTANCE pharynx, the bo
- Page 443 and 444: 430 DRUG RESISTANCE efforts for glo
- Page 445 and 446: 432 DRUG RESISTANCE and resistance
- Page 447 and 448: 434 MEDICAL IMPLICATIONS TABLE 17.1
- Page 449 and 450: 436 MEDICAL IMPLICATIONS TABLE 17.1
- Page 451 and 452: 438 MEDICAL IMPLICATIONS transmissi
- Page 453 and 454: 440 MEDICAL IMPLICATIONS H 2 C H H
- Page 455 and 456: 442 MEDICAL IMPLICATIONS parasites
- Page 457 and 458: 444 MEDICAL IMPLICATIONS neuropsych
- Page 459 and 460: 446 MEDICAL IMPLICATIONS of toxic f
- Page 461 and 462: 448 MEDICAL IMPLICATIONS Future con
- Page 463 and 464: 450 MEDICAL IMPLICATIONS Melarsopro
- Page 465 and 466: 452 MEDICAL IMPLICATIONS prevention
- Page 467 and 468: 454 MEDICAL IMPLICATIONS resulting
- Page 469 and 470: 456 MEDICAL IMPLICATIONS for S. ste
- Page 471 and 472: 458 MEDICAL IMPLICATIONS are though
- Page 473 and 474: 460 MEDICAL IMPLICATIONS FIGURE 17.
- Page 475 and 476: 462 MEDICAL IMPLICATIONS Marr, J.J.
- Page 477 and 478: 464 INDEX Aldolase, 143 Plasmodium
- Page 479 and 480: 466 INDEX Ascofuranone, 143 ASCUT-1
- Page 481 and 482: 468 INDEX Cnidarians, RNA trans-spl
- Page 483: 470 INDEX Entamoeba, 125 Ca 2 metab
- Page 487 and 488: 474 INDEX Ivermectin, 398, 427, 455
- Page 489 and 490: 476 INDEX Maduramicin, 412 Major va
- Page 491 and 492: 478 INDEX Nitric oxide: neurotransm
- Page 493 and 494: 480 INDEX calcium-binding proteins,
- Page 495 and 496: 482 INDEX Pyrimidine transport, 200
- Page 497 and 498: 484 INDEX Succinate:rhodoquinone ox
- Page 499 and 500: 486 INDEX genome, 21 survey sequenc
- Page 501: 488 INDEX U small nuclear RNA (snRN